The Role of HER2, EGFR, and Other Receptor Tyrosine Kinases in Breast Cancer

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2016 Dec 4

PMID 27913999

Citations 153

Authors

Jennifer L Hsu

Mien-Chie Hung

Affiliations

Soon will be listed here.

Abstract

Breast cancer affects approximately 1 in 8 women, and it is estimated that over 246,660 women in the USA will be diagnosed with breast cancer in 2016. Breast cancer mortality has decline over the last two decades due to early detection and improved treatment. Over the last few years, there is mounting evidence to demonstrate the prominent role of receptor tyrosine kinases (RTKs) in tumor initiation and progression, and targeted therapies against the RTKs have been developed, evaluated in clinical trials, and approved for many cancer types, including breast cancer. However, not all breast cancers are the same as evidenced by the multiple subtypes of the disease, with some more aggressive than others, showing differential treatment response to different types of drugs. Moreover, in addition to canonical signaling from the cell surface, many RTKs can be trafficked to various subcellular compartments, e.g., the multivesicular body and nucleus, where they carry out critical cellular functions, such as cell proliferation, DNA replication and repair, and therapeutic resistance. In this review, we provide a brief summary on the role of a selected number of RTKs in breast cancer and describe some mechanisms of resistance to targeted therapies.

Citing Articles

Preclinical evaluation of Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.

Usui T, Miyake T, Watabe T, Kato H, Yoshii Y, Naka S Breast Cancer Res. 2025; 27(1):33.

PMID: 40055744 PMC: 11889786. DOI: 10.1186/s13058-025-01972-4.

Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds.

Reymova F, Sever B, Topalan E, Sevimli-Gur C, Can M, Tuyun A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006082 PMC: 11859636. DOI: 10.3390/ph18020270.

The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.

Turova P, Kushnarev V, Baranov O, Butusova A, Menshikova S, Yong S NPJ Breast Cancer. 2025; 11(1):19.

PMID: 39979291 PMC: 11842814. DOI: 10.1038/s41523-025-00723-0.

Molecular Chimera in Cancer Drug Discovery: Beyond Antibody Therapy, Designing Grafted Stable Peptides Targeting Cancer.

Chowdhury A, Shrestha P, Jois S Int J Pept Res Ther. 2025; 31(3):38.

PMID: 39974747 PMC: 11832722. DOI: 10.1007/s10989-025-10690-6.

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.

Mihaylova R, Momekova D, Elincheva V, Momekov G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770542 PMC: 11677665. DOI: 10.3390/ph17121701.

References

Scaltriti M, Baselga J . The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006; 12(18):5268-72. DOI: 10.1158/1078-0432.CCR-05-1554. View

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

Orton T, Doughty S, Kalinowski A, Lord P, Wadsworth P . Expression of growth factors and growth factor receptors in the liver of C57BL/10J mice following administration of phenobarbitone. Carcinogenesis. 1996; 17(5):973-81. DOI: 10.1093/carcin/17.5.973. View

Reis-Filho J, Pinheiro C, Lambros M, Milanezi F, Carvalho S, Savage K . EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006; 209(4):445-53. DOI: 10.1002/path.2004. View

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

Du Y, Yamaguchi H, Wei Y, Hsu J, Wang H, Hsu Y . Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016; 22(2):194-201. PMC: 4754671. DOI: 10.1038/nm.4032. View

Von Zastrow M, Sorkin A . Signaling on the endocytic pathway. Curr Opin Cell Biol. 2007; 19(4):436-45. PMC: 1992519. DOI: 10.1016/j.ceb.2007.04.021. View

Witton C, Reeves J, Going J, Cooke T, Bartlett J . Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003; 200(3):290-7. DOI: 10.1002/path.1370. View

Lemmon M, Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-34. PMC: 2914105. DOI: 10.1016/j.cell.2010.06.011. View

10.

Gilbertson R, Hernan R, Pietsch T, Pinto L, Scotting P, Allibone R . Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer. 2001; 31(3):288-94. DOI: 10.1002/gcc.1146. View

11.

Psyrri A, Yu Z, Weinberger P, Sasaki C, Haffty B, Camp R . Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005; 11(16):5856-62. DOI: 10.1158/1078-0432.CCR-05-0420. View

12.

Nakai K, Hung M, Yamaguchi H . A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016; 6(8):1609-23. PMC: 5004067. View

13.

Morrison M, Hutchinson K, Williams M, Stanford J, Balko J, Young C . ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest. 2013; 123(10):4329-43. PMC: 3784526. DOI: 10.1172/JCI66764. View

14.

Koumakpayi I, Diallo J, Le Page C, Lessard L, Gleave M, Begin L . Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res. 2006; 12(9):2730-7. DOI: 10.1158/1078-0432.CCR-05-2242. View

15.

Chen Y, Huang W, Wei Y, Hsu S, Yuan P, Lin H . Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One. 2011; 6(6):e21428. PMC: 3121773. DOI: 10.1371/journal.pone.0021428. View

16.

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

17.

Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L . Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005; 280(35):31182-9. DOI: 10.1074/jbc.M506591200. View

18.

Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S . Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008; 10(1):R2. PMC: 2374953. DOI: 10.1186/bcr1843. View

19.

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

20.

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View